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Cancer cells are known to rely on the anaerobic energy pathway of glycolysis even under 
normoxic conditions, resulting in measurable intracellular acidification that may trigger cell 
death by apoptosis. In normal cells, the pH is restored by activation of voltage-gated proton 
pumps, preventing apoptosis. Proton pump inhibitors (PPIs), such as omeprazole, inhibit the 
action of these voltage-gated proton pumps. Research has shown that omeprazole is also capable 
of inducing caspase-dependent apoptosis in Jurkat T-lymphocytes, but this area of study remains 
largely unexplored. The goal of this research was to determine the temporal dynamics 
of caspase activity in Jurkat cells treated with omeprazole, dexlansoprazole, or esomeprazole. 
Caspase activation was observed with fluorescence microscopy and the fluorogenic caspase 
probe, L-bisaspartic acid rhodamine 110 (D2R). All three PPIs were shown to induce significant 
caspase activity when incubated in the presence of the drug over a 30-hour period, with 
dexlansoprazole showing comparative activity to the positive control, doxorubicin. Microfluidic 
devices were utilized to capture cells for real-time analysis, but only the doxorubicin showed 
caspase activity during these trials, with an onset time of 3.66 ± 1.67 hours. The microfluidic 
device experiments showed a decrease in cell-to-device binding affinity following the incubation 
period, indicating that PPI exposure alters the cell surface receptors in some capacity. Future 
studies will focus on addressing these challenges to allow for the elucidation of the intensity and 
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1.1 Cancer and its Survival Mechanisms 
 In 2021, 608,570 cancer deaths are predicted to occur in the United States (Siegel, 2021). 
Although treatment options for cancer have been widely expanded over the last century, many 
human solid tumors remain troublesome to treat. Major problem areas of existing therapies 
include general systemic toxicity associated with drugs, acquired resistance to chemotherapeutic 
drugs (multi-drug resistance), and disruption of drug efficacy in acidic environments (Fais, 
2010). Cancer cells favor increased glucose uptake and fermentation of glucose to lactate, even 
when in the presence of ample oxygen (Liberti, 2016). This phenomenon, known as the Warburg 
Effect, works in conjunction with regional hypoxia and nutrient deficiency to result in a 
measurable acidification of the interior of the cancer cells (Damaghi, 2013). Cancer cells 
proliferate optimally when they exhibit a slightly alkaline pH, around 7.0-7.6, and will begin to 
undergo metabolic stress if the intracellular pH falls below 6.7 (Persi et al., 2018). Thus, if left 
unregulated, this intracellular acidification caused by the Warburg Effect results in the induction 
of apoptosis (Gottlieb et al., 1996; Sharma et al., 2015; and Lagadic-Gossmann et al., 2004).  
To avoid this fate, cancer cells maintain survivable pH levels via the overexpression and 
upregulated activation of plasma membrane proteins, including pumps and transporters, to 
facilitate the release of H+ ions to raise the alkalinity of the cell’s interior (Huber et al., 2010). 
These pathways create a reverse pH gradient compared to normal cells, in which the cancer cell’s 
interior is more alkaline than its environment (Persi et al., 2018). The cells release lactate and H+ 
via monocarboxylate transporters (Gillies, 2002) and Na+-driven proton extrusion (Gallagher et 
al., 2008), turning their extracellular environment acidic (Figure 1). When these pathways 
malfunction or are subjected to inhibition via drugs, the efflux of H+ can no longer take place, 
	 4 
resulting in the acidification of the cell’s intracellular environment, and eventually leading to cell 
death. Further methods of pH regulation vary by cell type but may include carbonic anhydrases 
(Barathova et al., 2008) or V-ATPase, a vacuolar-type H+/K+-ATPase (Hinton et al., 2009).  
 
Figure 1: The extrusion of protons (shown in blue) performed by a typical cancer cell. The cell 
employs several methods of maintaining intracellular alkalinity, including sodium-driven proton 
extrusion, V-ATPase activity, and monocarboxylate transporters (MCT). The overexpression of 
these mechanisms leads to a measurable acidification of the extra-cellular environment (Huber et 
al., 2010). Image created in BioRender.com. 
 
V-ATPase has been shown to be particularly important for cancer cell survival, acting as 
a promoter of proliferation and metastasis by facilitating the acidification of the extracellular 
environment as it maintains the pH within the cell (von Schwarzenberg, 2013 and Wiedmann, 
2012). In cancer, V-ATPase expression is upregulated to maintain a survivable pH within the cell 
(Nelson and Harvey, 1999). Elevated expression of V-ATPase mRNA has been associated with 
poor survival in ovarian cancer patients (Lee et al., 2015), suggesting that regulation of V-
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ATPase expression is essential for increasing the chances of patient survival. The inhibition of 
V-ATPase has been shown to limit cancer proliferation and induce apoptosis in a variety of cell 
lines (Whitton, 2018), as it leads to an increased expression of the pro-apoptotic tumor-
suppressor protein p53 (Williams et al., 1999 and Long et al., 1998). Since intracellular 
acidification has been shown to precede caspase activation in cells undergoing mitochondria-
dependent apoptosis (Matsuyama, 2000), drugs which lead to intracellular acidification may be 
viable for cancer therapies. These findings suggest that inhibition of V-ATPase is a valuable 
target for anti-cancer research, particularly where the induction of apoptosis in tumor cells is 
desired. 
 
1.2 Apoptosis and the Caspases 
Apoptosis, or programmed cell death, is characterized by distinct biochemical 
mechanisms (Elmore, 2007). It is essential for normal cell turnover, maintenance of tissue 
homeostasis, immune system regulation, and many other critical biological processes. Improper 
regulation of apoptosis can lead to neurodegenerative diseases, ischemic damage, and 
autoimmune disorders (Elmore, 2007), and is widely recognized as the most common cause of 
cancer development (Finkel, 2001). Apoptosis proceeds via the extrinsic pathway, where the cell 
responds to external signals, or the intrinsic pathway, which results from internal stimuli. The 
role of PPIs in cancer cell death is currently attributed to the function of the intrinsic pathway. 
The loss of apoptotic suppression seen in this pathway may be due to the absence of growth 
factors, hormones, and cytokines that would typically inhibit the death of the cell (Elmore, 
2007). Pro-intrinsic-apoptosis signals can also include radiation, toxins, hypoxia, hyperthermia, 
infection by bacteria or viruses, and free radical oxidative stress (Susin et al., 2000). 
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Pro-apoptotic signals result in changes to the inner mitochondrial membrane that cause 
the cascade of apoptosis (Figure 2) to begin. These signals trigger the mitochondrial permeability 
transition (MPT) pore to make a conformational change to the open position (Elmore, 2007). 
This change results in the loss of the mitochondrial transmembrane potential and the release of 
granzyme b into the inner membrane space, facilitating the movement of pro-apoptotic proteins 
cytochrome c, Smac/DIABLO, and HtrA2/Omi into the cytosol, where they activate the caspase-
dependent mitochondrial pathway of apoptosis (Saelens et al., 2004; Cai et al., 1998; Du et al., 
200; Loo et al., 2002; Garrido et al., 2005). 
 
Figure 2: The cascade of apoptosis, beginning with the example stimulus of severe DNA 
damage. Pro-apoptotic signals, like the Bax protein, facilitate the release of cytochrome c from 
the mitochondria. Cytochrome c binds to APAF-1, forming the apoptosome complex, where the 
procaspase-9 is cleaved to the active caspase-9 form. Caspase-9 activates the executioner 
caspase-3 which cleaves the death substrates and goes on to cleave other caspases to facilitate the 
amplification of the apoptotic signal (Saelens et al., 2004; Cai et al., 1998; Du et al., 2000; Loo 




Caspases, a family of cysteine proteases, cleave their substrates on the C-terminus of 
aspartic acid residues to drive the signaling cascade of caspase-dependent apoptosis (Julien and 
Wells, 2017). Once the pro-apoptotic proteins move to the cytosol, cytochrome c binds to the 
protease adaptor APAF-1, and the complex binds to procaspase-9, forming the apoptosome and 
leading to the activation of caspase-9, the initiator caspase for the intrinsic pathway (Chinnaiyan, 
1999). Once caspase-9 is active, the full cascade effect of apoptosis begins, as active caspases 
auto-catalytically cleave additional caspases, resulting in significant and exponential 
amplification of the initial signal (Poreba, 2015). As such, apoptosis is an “all or nothing” 
process; once the caspase cascade begins, it continues autonomously. Smac/DIABLO and 
HtrA2/Omi inhibit the activity of proteins that normally suppress apoptosis, aiding the activation 
of the apoptotic cascade (Loo et al., 2002). 
In the execution phase of apoptosis, the effector caspases are activated (Elmore, 2007). 
These “executioner” caspases activate cytoplasmic endonuclease and other proteases, leading to 
the degradation of the nuclear material and nuclear and cytoskeletal proteins. Executioner 
caspases resulting in the blebbing and budding of the plasma membrane and the orderly death of 
the cell (Slee et al., 2001). Caspase-3 is recognized as the most important effector caspase, as it 
cleaves the endonuclease inhibitor of caspase-activated DNase (ICAD) to release CAD, which 
then degrades chromosomal DNA and leads to chromatin condensation (Sakahira et al., 1998). 
Caspase-3 also triggers the formation of the apoptotic bodies and is responsible for the cleavage 
of gelsolin, which results in disruption of the cytoskeleton, intracellular transport, cell division, 
and signal transduction (Kothakota et al., 1997). The function of caspase-3, as well as the other 
effector caspases and the initiator caspases that activate them, is essential for the occurrence of 
apoptosis and the regulation of cell turnover in a manner that is not disruptive or damaging to the 
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surrounding tissues. 
A hallmark of apoptosis is the absence of an inflammatory reaction to cell death 
(Kurosaka et al., 2003). As the apoptotic cell undergoes controlled death, the cellular membrane 
experiences blebbing which is then followed by karyorrhexis and budding (Figure 3), where the 
cell fragments separate into compact apoptotic bodies (Elmore, 2007). These apoptotic bodies 
are quickly phagocytosed by macrophages, preventing secondary necrosis and eliminating the 
production of anti-inflammatory cytokines (Savill and Fadok, 2000; Kurosaka et al., 2003). The 
lack of inflammatory response and avoidance of necrosis makes apoptosis the most orderly and 
least disruptive form of cell death. Unfortunately, cancer cells employ several regulatory 
pathways to inhibit apoptosis (Shen, 2010), and upregulation of V-ATPase to maintain 
intracellular alkalinity is just one method. Furthermore, many cancer cell lines show resistance to 
the caspase-9 pathway of apoptosis (Reif, 2010). Drugs that restore normal levels of caspase-
dependent apoptosis represent promising treatment strategies (Wong, 2011). Drugs that return 
expression of the V-ATPase to normal levels, or compensate for its overexpression, remain 





Figure 3: The cycle of physical symptoms of apoptosis exhibited by dying cells. The cellular 
membrane begins to undergo blebbing, which is joined by karyorrhexis. Blebbing and 
fragmentation of the nuclear material continue to occur until the cell is broken up into small 
apoptotic fragments which are then engulfed by surrounding macrophages (Elmore, 2007). 
Image created in BioRender.com. 
 
 
1.3 Proton Pump Inhibitors 
Proton pump inhibitors are a class of drugs with the specific purpose of inhibiting gastric 
acid secretion by inhibiting gastric V-ATPase on the luminal surface of the parietal cell 
membrane (Shin, 2010). Gastric V-ATPase is the enzyme responsible for secreting gastric acid 
via an electroneutral, ATP-dependent hydrogen-potassium exchange mechanism, pumping K+ 
into the cell and H+ out of the cell (Sachs, 1976). Gastric V-ATPase has an identical function to 
that observed in cancer cells exhibiting the Warburg Effect. This makes the PPIs, which inhibit 
gastric V-ATPase, potential targets for inhibiting cancer V-ATPase activity. 
PPIs are commonly utilized as a secondary or supportive treatment to cancer therapies, as 
the acidity of cancer cells presents problems for targeted anti-tumor treatments, which are 
commonly weak bases (Fais, 2010). These weak bases encounter the extracellular environment 
of the tumor cell, which is acidic due to the cell’s pH-regulating process, and are protonated, at 
which point they are no longer membrane-permeable (Fais, 2010). PPIs have been shown to 
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inhibit V-ATPase pathways, resulting in intracellular acidification that makes the tumor cells 
more susceptible to anticancer agents (Ikemura, 2017). The drugs are most often taken orally for 
their traditional anti-acid applications, but may also be administered intravenously or via direct 
injection, making them more bioavailable for proton pump inhibition at a faster rate (Wu et al., 
2019). 
The pharmacophore of all PPI drugs is 2-pyridylmethylsulfinylbenzimidazole, and the 
constituent R groups vary from drug-to-drug (Figure 4) (Roche, 2006). The chemical reactivity 
and inhibitory potency of the drugs is heavily influenced by the electron-donating or electron-
withdrawing nature of the substituents (Roche, 2006). Upon initial application to the body, the 
PPIs exist in a pro-drug or inactive form. To convert the inactive PPIs to their active, inhibitor 
forms, both the pyridine and benzimidazole rings must be protonated according to their pKa 
values (Shin and Kim, 2013 and Roche, 2006). The pyridine nitrogen is protonated first at a pKa 
ranging from 3.83 to 4.53 (Figure 5) (Roche, 2006). In their traditional applications, this first 
protonation occurs once the drug is already uptaken by the gastric parietal cells, and will render 
the drug membrane-impermeable, so it cannot leave the cell. The second protonation of the 
benzimidazole nitrogen follows immediately at a pKa ranging from 0.11 to 0.79 (Roche, 2006). 
This protonation generates the monocation of the charged benzimidazole ring and the unionized 
pyridine ring, which can conduct an intramolecular nucleophilic attack to produce sulfenamide 
and sulfenic acid. These products form covalent disulfide bonds with the sulfhydryl groups on 
the CYS813 or CYS822 residues in the V-ATPase enzyme, holding it in the inactive 
conformation. This inhibition of V-ATPase is thus irreversible, and the acid-secretion ability of 
V-ATPase is terminated (Roche, 2006). The body must synthesize new V-ATPase enzymes for 
acid secretion to resume. 
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The parietal cells the PPIs normally target have a low intracellular pH around 0.8, 
meaning their intracellular environment is where protonation and the action of the PPIs takes 
place (Roche, 2006). However, this is not the case for cancer cells, which exhibit an intracellular 
pH that is alkaline. Instead, the protonation and activation of the PPIs is believed to occur in the 
cancer cell’s acidic microenvironment (Lu et al., 2017). It remains unknown whether the cancer 
cells can up-take the PPIs, or whether the drug’s inhibitory effects occur solely in the cells 
immediate external environment. It is hypothesized that the PPIs are activated to form their 
reactive sulfenamide and sulfenic acid compounds and still form disulfide bonds with the V-
ATPase’s cysteine residues on the extracellular portion of the transmembrane enzyme, but the 
specific residues remain largely unexamined (Lu, et al., 2017). 
 
 
Figure 4: The structures of the PPIs utilized in this study. The basic structure of the 
benzimidazole and pyridine rings are consistent for each drug, but various constituent groups 
differ. The electron-donating or electron-withdrawing nature of these constituents influences 





Figure 5: The overview of the mechanism of activation of the PPIs. The first step is protonation 
of the pyridine nitrogen, followed by the protonation of the benzimidazole nitrogen. Two 
monocations of the protonated benzimidazole structure exist; one with an ionized pyridine 
nitrogen and one with an unionized pyridine nitrogen. It is the monocation with the unionized 
monocation that can undergo an intramolecular nucleophilic attack to generate the active sulfenic 
acid and sulfenamide products. These products readily form disulfide bonds with sulfhydryl 
groups in the cysteine residues of V-ATPase, and thus inhibit the enzyme’s acid-secretion 
function. (Image taken from Shin and Kim, 2013). 
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Despite the mechanism remaining largely unknown, the inhibiting effects of the PPIs 
have shown increased sensitization of cancer cells to chemotherapeutics, translating to a 
reduction in drug resistance (De Milito and Fais, 2005). Omeprazole and esomeprazole were 
shown to enhance the effects of anticancer agents through inhibition of V-ATPase in human 
melanoma, adenocarcinoma, and lymphoma (Luciani et al., 2004). Furthermore, omeprazole was 
shown to induce apoptosis in Jurkat cells via cleavage of procaspase-3 and PARP (Scaringi, 
2004). This is promising, since caspase-3 is the most important effector caspase, and it partakes 
in many of the cleavage steps that directly result in membrane blebbing and chromatin 
condensation. Although studies have shown that PPIs can induce cell death via a caspase-
independent pathway involving reactive oxygen species (Canitano et al., 2016 and De Milito et 
al., 2007), current methods of treatment view PPIs as primarily supportive care. PPIs have 
additional benefits as therapeutics, as they only become active in acidic environments, meaning 
they can selectively target tumor cells, and they generally carry only mild side effects (Walsh, 
2015). Existing chemotherapeutic agents are commonly cell-cycle-specific, and can only 
eliminate cancer cells when they are actively dividing. This presents another problem with drug 
resistance, as human tumors often contain cells that proliferate very slowly (Dey-Guha, 2011). 
This leaves behind residual cancer cells that eventually divide and reform the tumor.  
Chemotherapeutics which are non-cell-cycle-specific, such as doxorubicin, are generally 
toxic to the system. These drugs often confer serious side-effects and are non-specific to 
targeting cancer cells. Instead, the agent destroys all cells it encounters, leading to the damaging 
of the patient’s tissues that can be permanent (Johnson-Arbor and Dubey, 2021). Among the 
most common chemotherapy side effects are nausea and vomiting (Rapoport, 2017). 
Manifestations of nausea and vomiting come in the acute form, which is reasonably treatable, 
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and the delayed form, which is poorly manageable (Rapoport, 2017). Additional gastrointestinal 
side-effects are commonly seen in chemotherapy, including oral and gastrointestinal mucositis 
(Cinausero et al., 2017). Uncontrolled chemotherapy-induced diarrhea is also common, with 
potentially fatal consequences of dehydration and electrolyte imbalance, and may require 
reductions or cessations of treatment (Nurgali, 2018). Cognitive impairments may manifest or 
persist long after the end of treatment (Castel et al., 2017). Chemotherapy-induced peripheral 
neuropathy (CIPN) is also very common, and can cause a host of different symptoms (Nurgali, 
2018). Long-term CIPN is associated with depression, ataxia, insomnia, and gastrointestinal 
dysfunction (Kerckhove et al., 2017). While some advancements have been made in reducing the 
severity or duration of these side-effects, they persist frequently in patients undergoing 
chemotherapy. Doxorubicin, the positive control in this study, is capable of inducing 
cardiomyopathy at any point following treatment. Doxorubicin-induced cardiomyopathy has no 
cure and will persist throughout the duration of the patient’s life, eventually contributing to an 
earlier mortality (Johnson-Arbor and Dubey, 2021).  
Proton pump inhibitors are well-tolerated in clinical administrations, with serious adverse 
events being extremely rare (Thomson, 2010). The most common concern reported with long-
term or acute PPI usage is rebound acid reflux upon the cessation of treatment. Long-term use of 
PPIs has not been shown to cause carcinoid tumors or increase the risk of gastric cancers, 
although some links are currently being investigated (Thomson, 2010). PPIs have been proven to 
be safe and effective in managing gastrointestinal reflux disease, healing peptic ulcers, and 
reducing gastritis. They have become one of the most-prescribed medications employed by 
healthcare providers in modern medicine (Ambizas, 2017). These drugs are associated with an 
increased risk of developing community-acquired pneumonia, which could be risky for 
	 15 
immunocompromised patients, such as those undergoing chemotherapy (Johnson, 2013), but are 
generally well-tolerated by the body. The lack of reported adverse effects and the generally low 
toxicity of PPI drugs make them not only safe for use as supportive therapy, but also affirm their 
potential as standalone, low-toxicity therapeutic agents. 
Since PPI drugs are non-cell-cycle-specific but are generally nontoxic to the normal cells 
and tissues, and trigger both caspase-dependent and caspase-independent apoptosis, they may be 
more effective in drug-resistant or apoptosis-resistant forms of cancer. Inducing the same levels 
of death in cancerous cells while maintaining the viability of the normal tissues could bring forth 
a breakthrough in lowering the toxicity of cancer treatments. However, little research has been 
conducted to uncover the temporal dynamics of caspases and biochemical mechanisms within 
apoptotic PPI pathways. Furthermore, the apoptotic capabilities of other commercially-available 
PPI drugs, including new-generation PPIs like dexlansoprazole, have not yet been documented. 
Thus, this study seeks to elucidate the apoptotic effects of select PPI drugs on Jurkat cells via 
real-time monitoring of caspase activity. 
 
1.4 Temporal Dynamics of Caspase Activation 
Caspase activation and inhibition present major fields of study in cancer research. 
Unfortunately, cancer cells are notorious for being resistant to apoptosis, and multidrug 
resistance is rampant across cell lines (Fais, 2010). This presents problems for traditional 
caspase-targeted therapies, and often renders them ineffective. In cases where the inhibition of 
caspases is selected as a course of treatment, the cell will often die via caspase-independent 
pathways, including the lysis of cells resulting from granule exocytosis (Kolenko, 2000). 
Caspase-independent pathways of apoptosis have recently showed promise in emerging studies, 
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yet present their own unique problems. Caspase-independent pathways are often pro-
inflammatory, resulting in the recruitment of inflammatory cytokines (Giampazolias, 2018). 
While the triggering of the immune inflammatory response can be harmful in some cases, 
(Ammirante et al., 2010), the host immune response can be utilized to aid the body’s response to 
chemotherapy (Zitvogel et al., 2008).  
Prior research has been conducted to examine the general timing of caspase activity in 
living cells undergoing apoptosis as a natural event, but the temporal dynamics of caspases 
remains largely unknown. Caspase-3 activation has been shown to occur seven hours post-
induction (Sundquist et al., 2006). Further data exists on caspases involved in the extrinsic 
pathway, but very little is known about the timeline for caspase activation in the intrinsic 
pathway. Furthermore, individual cellular assays could provide a more robust outline of caspase 
activation than multi-cell studies. Microfluidic devices designed by Reif et al. in 2009 (Figure 6) 
provide an affinity surface for cell capture, while maintaining gas and waste exchange and 
allowing for a continuous medium supply. Cells may be bound to the affinity surface via 
antibodies, which have been utilized extensively in cell affinity chromatography (Pappas, 2007). 
The Reif et al. device utilizes an affinity ladder of biotinylated bovine serum albumin (BSA), 
NeutrAvidin, and anti-CD71 to hold cells stationary for observation. When the cells pass through 
the microfluidic channel, those expressing the cell surface receptors corresponding to anti-CD71 
are retained in the affinity column. The antibody ladder (Figure 7), which is applied according to 
a procedure by Kuida et al., is carefully selected to contain an antibody that does not induce 
apoptosis (Reif, 2009). Once cells are bound to the affinity channel, they remain viable for up to 
ninety-six hours (Liu, 2008), allowing for long periods of observation. 
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Figure 6: The microscope setup with a zoom-in of the Reif et al. microfluidic device. The device 
features a PDMS polymer housing with a molded microfluidic channel for cell capture. For 
experimentation, the device is connected to a Y-junction of Teflon tubing, which is then attached 




Figure 7: The antibody ladder utilized for cell capture. Biotinylated BSA is applied to the 
microscope slide. The NeutrAvidin is then applied, which binds to the BSA. The detection 
antibody, anti-CD71 is then applied to the NeutrAvidin layer. Image created in BioRender.com. 
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Apoptosis can be observed in captured cells utilizing fluorescence microscopy and 
fluorogenic probes. Rhodamine 110 (R110) is a naturally fluorescent, membrane-impermeable 
molecule known as a fluorophore (Reif et al., 2010). Conjugation of specific tetrapeptide 
sequences to the R110 molecule renders it non-fluorescent and membrane-permeable, allowing it 
to be utilized as a fluorogenic caspase probe. Cells uptake the conjugated molecule, (Asp)2-
rhodamine 110 (D2R), where its covalently-bound aspartic acid residues, are susceptible to 
cleavage by active caspases. Active caspases recognize and cleave the aspartic acid tetrapeptide 
substituents on the non-fluorescent R110 molecule, freeing R110 and converting it to its mono-
substituted form, which fluoresces when excited with 488 nm LED light (Martinez, 2010). The 
fluorescent molecule is released upon cleavage and remains within the cell, allowing for the 
detection of caspase activity (Figure 8). Once the aspartic acid residues are cleaved, the free 
R110 molecule is again membrane-permeable, but will leave the cell at a very slow rate. Thus, 
when real-time observation is conducted, the amount of fluorescence detected in a D2R-treated 
cell correlates directly to the amount of caspase activation occurring in the cell (Martinez, 2010). 
These methods, when combined with the use of affinity surfaces for observation of the cells, 
allow for the measurement of caspase activity in response to drug treatment over a period of 




Figure 8: The process of a caspase cleaving the aspartic acid residues from the D2R molecule. 
Once cleaved, the R110 fluorophore returns to its native fluorescent form. Since D2R is absorbed 
into the cytosol of the cell, the cleaved R110 fluorophore is retained for a period, and the cancer 
cell will fluoresce upon excitation with 488 nm light. Image created in BioRender.com. 
 
In this work, various PPI drugs were evaluated for their ability to induce caspase-
dependent apoptosis in Jurkat T lymphocytes. Induction of mitochondrial apoptosis was verified 
utilizing cell affinity capture and fluorescence microscopy. Once drugs were shown to induce 
apoptosis, temporal dynamics assays were performed to determine the timeframe for general 
caspase activity. Preliminary microscopy studies displayed a broad outline of the duration of 
total caspase activation and leveling, and these results provided the period of observation for use 
in the microfluidic device trials. The elucidation of the capabilities of PPIs to induce caspase-
dependent apoptosis could outline less systematically toxic therapeutic alternatives to traditional 
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cancer treatments. Furthermore, the identification of the temporal dynamics of specific caspases 
activated by PPIs could prove beneficial for targeted caspase therapies, which may employ PPIs 
as standalone anticancer agents. 
 
2. MATERIALS AND METHODS 
2.1 Microfluidic Device Fabrication 
 The procedure for the fabrication of the microfluidic devices used in this study was 
adapted from the original study by Reif et al. in 2009. Poly(dimethylsiloxane) pre-polymer 
(Ellesworth Adhesives) and Dow Sylgard 184 cross-linking agent (Ellesworth Adhesives) were 
combined in a 10:1 ratio (w/w). The solution was mixed vigorously for five minutes, degassed in 
a vacuum chamber until no air bubbles remained, and poured into a machined mold. This mold 
was cured for two hours at 80°C and then cooled to room temperature. The cured PDMS was cut 
into pieces approximately two inches by two inches, and adhered to a glass microscope slide 
(Fisher Scientific) with additional uncured PDMS polymer. After adhering, the mold was cured 
at 80°C for fifteen minutes and allowed to cool. A one-inch section of 220 µm glass capillary 
(Trajan Scientific and Medical) was inserted into the channel and additional uncured PDMS was 
administered to the area around the capillary and along the edges of the device to prevent 
leakage. After a final curing period of fifteen minutes at 80°C, the devices were tested to ensure 
proper function and stored for coating. 
 
2.2 Coating of Microfluidic Devices with Antibody Ladder 
 Coating of the affinity surface was performed according to the Kuida et al. procedure, 
with NeutrAvidin taking the place of streptavidin to reduce non-specific binding (Reif et al., 
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2010). Tubes were fashioned from 30-gauge Teflon tubing (SGE Analytical Science) and 200 
series barbs (Cole Parmer Instrument) for the administration of liquid. LEUR-LOK tip, 3 mm 
syringes (Dickinson and Company) were utilized to push liquid into the tubing for application in 
the microfluidic device. The microfluidic channel was first rinsed with 70% ethanol and 1x T50 
buffer (10 mM Tris-HCl, pH 8, 50 mM NaCl). Biotinylated BSA (1mg/mL in T50 buffer) 
(Fisher Scientific) was then added to the affinity channel and allowed to coat for forty-five 
minutes. Subsequently, the protein was cleared from the channel with air and additional 1x T50 
buffer. NeutrAvidin (0.2 mg/mL in T50 buffer) (Fisher Scientific) was then added to the channel 
and allowed to coat for twenty minutes. The channel was then cleared with additional T50 buffer 
and dried with air, at which point the device could be stored at 4°C for up to two months before 
use. On the day of the experiment, biotinylated-anti-CD71 (50 µg/mL in PBS, pH 7.2, with 0.1% 
gelatin) (Fisher Scientific) was applied to the microfluidic channel and allowed to coat for 
twenty minutes. Devices were utilized immediately following the antibody coat. 
 
2.3 Preparation of PPIs, Doxorubicin, and Fluorogenic Probe 
 All PPIs and the positive control drug, doxorubicin, were purchased from Sigma Aldrich. 
The protocol for PPI preparation was adapted from Scaringi et al. to account for the differing 
solubility of each drug. Omeprazole was dissolved in polyethylene glycol (PEG) 200 (Sigma 
Aldrich) to make a 20 mM stock solution. Dexlansoprazole was dissolved in DMSO to make a 
50mM stock solution. Esomeprazole was dissolved in DMSO to make a 650 mM stock solution. 
The positive control drug, doxorubicin, was dissolved in DMSO to make a 20 mM stock 
solution. These concentrated solutions were stored in small aliquots at -20°C and thawed just 
before an experiment. All PPIs were diluted down to 1.0mM upon incubation with the cells and 
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fluorogenic probe at a total volume of 2000 µL. The fluorogenic probe, D2R (20 µM) (Sigma 
Aldrich), was suspended in DMSO.  
 
2.4 Cell Culture 
 Jurkat T lymphocytes were cultured in RPMI 1640 medium (Hyclone) containing 10% 
fetal bovine serum (FBS) and 1% penicillin-streptomycin (Fisher Scientific) and maintained in 
an incubator at 37°C and 5% CO2 atmosphere. Sub-cultures were performed every three days in 
a laminar flow tissue culture hood (BSL-2) to ensure cell viability and to keep up with the 
schedule of experiments. To prepare for experimentation, cells were centrifuged twice at 4000 
rpm for five minutes in an Eppendorf microcentrifuge 5425, with a resuspension in 1x 
phosphate-buffered saline (PBS) occurring in-between centrifugations. After washes, the cells 
were transferred to a 35 mm petri dish (Greiner) for incubation with the target drug.  
 
2.5 Baseline Caspase Activation Study 
 A baseline study was conducted to confirm that the selected drugs induced caspase 
activity in any capacity. Experimental samples were run synchronously with a positive and 
negative control, utilizing the same Jurkat cells for each sample. Fifteen milliliters of Jurkat cells 
were harvested, washed twice with 1x PBS, re-suspended in three milliliters of complete 
medium, and divided amongst three petri dishes. The selected PPI drug was added to the 
experimental petri dish at a concentration of 1.0 mM. Doxorubicin was added to the positive 
control dish at a concentration of 100 µM. No PPIs were added to the negative control dish. For 
all samples, 6 µL of D2R was added directly to the culture dish (2 µL/mL). The probe was added 
at the same time as the PPI drug for the experimental dishes. The six-hour incubation period 
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began immediately following the addition of the fluorogenic probe to each sample. Equivalent 
amounts of either PEG 200 or DMSO were added to the negative control dishes to be congruent 
with the amount of drug solvent in the experimental sample. The total volume during incubation 
was initially two milliliters. At time zero of this period, 200 µL of cells were collected from the 
petri dishes and washed twice with 1x PBS for imaging.  
During the incubation period, the petri dishes were stored in the incubator at 37°C and 
5% CO2 atmosphere to maintain cell viability. At hour six, the total volume of cells was 
harvested from each petri dish. These harvests were washed three times with 1x PBS, and 
another 200 µL of washed cells was collected from each for imaging. The remaining cells were 
re-suspended in complete medium with 6 µL of D2R at a total volume of five milliliters per dish 
and placed back in the incubator. Cells were harvested from each sample in aliquots of 500 µL 
for imaging at hours twelve, eighteen, twenty-one, twenty-four, twenty-seven, and thirty from 
the time of exposure to the drug. All images in this study were taken with a Nikon Monochrome 
Microscope Camera (DS-Ri2) connected to an inverted microscope (Eclipse Ts2R-FL). White 
light images (exposure 20 ms, DIA filter, phase contrast 2) and green light fluorescence images 
(exposure 1000 ms, green light filter, phase contrast 2, 100-W Hg lamp) were taken of each 
aliquot. The 10x microscope objective was utilized for the baseline study to capture a greater 
number of cells. These images were saved for later analysis. Baseline activation studies were 
repeated in triplicate for each drug and the controls. 
 
2.6 Temporal Detection of Caspase Activity 
 For the temporal dynamics trials, microfluidic devices were utilized for the capture and 
observation of the cells. Fifteen milliliters of Jurkat cells were harvested, washed twice with 1x 
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PBS, and re-suspended in a petri dish in two milliliters of complete medium with the selected 
PPI drug and the fluorogenic probe. The petri dish was stored in the incubator at 37°C and 5% 
CO2 for the six-hour drug incubation period. Upon the completion of this period, the total cell 
volume was harvested, washed three times with 1x PBS, and re-suspended in complete medium 
containing the fluorogenic probe. The cells remained in the incubator for an additional fifteen to 
eighteen hours before being harvested for device observation. After the drug incubation period, a 
microfluidic device was coated with anti-CD71 for twenty minutes. This device was connected 
to a Y-junction prepared from Teflon tubing, and secured to the microscope stage. The 
experimental cells were harvested, washed twice with 1x PBS, re-suspended at a final volume of 
one milliliter, and transferred to a syringe. During the antibody coating period and cell 
centrifugations, a solution of FBS-PBS was prepared. One milliliter of 10x FBS was combined 
with one milliliter of 10x PBS. This solution was diluted to ten milliliters, at which point three 
milliliters were collected, combined with 6 µL fluorogenic probe, and transferred to a syringe. A 
third syringe of 1x PBS was also prepared. Once the cells were introduced to the channel, the 
cell syringe was swapped for the 1x PBS syringe. The FBS-PBS and 1x PBS syringes remained 
attached to the pumps for the duration of the experiment, and alternated pushing liquid through 
the microfluidic channel. The 1x FBS – 1x PBS syringe was needed to maintain cell viability and 
expose the cells to the probe. The 1x PBS syringe was required to clear excess fluorogenic probe 
from the observable cell field to reduce background fluorescence during analysis. 
 After device coating and cell washing, the syringes were connected to the Y-junction and 
mounted to automated syringe pumps (Kd Scientific). The experiment was limited by the 
presence of only two pumps, so the cell syringe was attached for long enough to flood the 
channel with a sufficient quantity of cells, and then it was swapped for the PBS syringe. When at 
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least one hundred observable cells were present in the channel and the syringes were secured, the 
cells were allowed a twenty-minute binding period. This binding period was essential for the 
adherence of cells to the affinity surface. After the binding period, the FBS-PBS pump was run at 
1.5 mL/hour for three minutes to remove unbound cells from the device. This also flooded the 
channel with the solution containing the fluorogenic probe. Since an excess of fluorogenic probe 
solution would cause too much background fluorescence for imaging, the PBS syringe was then 
run at 0.25 mL/hour for ten minutes. Following the PBS wash, the time zero imaging was 
conducted, marking the beginning of the six-hour observation period. During this period, images 
were taken every twenty minutes. Between images, the FBS-PBS syringe was first run for ten 
minutes at 0.15 mL/hour, followed by the PBS syringe for ten minutes at 0.25 mL/hour. This 
time course for the pumps ensured cell viability and sufficient exposure to the fluorogenic probe 
while also maintaining the low fluorescence intensity of the background. The white light and 
green light images were saved for later analysis. 
 
2.7 Binding Affinity Study 
 To determine if PPI treatment affected the ability of cells to bind to the affinity surface, a 
binding study was conducted. Cells were harvested and incubated using the incubation protocol 
from the baseline activation study, including the addition of the fluorogenic probe and the re-
suspension in complete medium after the incubation period to remove the PPIs from the 
suspension. A 500 µL aliquot of cells was removed and washed with 1x PBS every six hours for 
imaging on a microscope slide and on a microfluidic device. A single set of white light and green 
light images was taken for each sample on the microscope slide to verify the presence of 
fluorescence. The remaining sample cells were introduced to the microfluidic device channel and 
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allowed to bind for a period of twenty minutes, at which point pre-wash white light and green 
light images were taken. The channel was then washed with 1x PBS for three minutes to remove 
unbound cells. Post-wash white light and green light images were then taken. Each experimental 
sample was accompanied by a negative control with no added PPI, to be examined congruently. 
The experimental sample and the conjugate negative control sample utilized the same cells. The 
same microfluidic device was utilized for all three experiments, which were run back-to-back. 
Prior studies verified the reusability of the microfluidic devices over a period of three days with a 
re-coating of anti-CD71 in-between trials. To establish the percentage of cells that successfully 
bound to the channel, the post-wash cell count was compared to the pre-wash cell count taken 
from the respective white light images. The presence of fluorescence in the pre-wash images 
versus that observed in the post-wash images was also noted to determine if cells exhibiting PPI-
induced caspase activity were selectively unable to bind to the channel. 
 
2.8 Analysis of Images 
 All white light and green light images were processed utilizing ImageJ software (v. 1.4.1, 
National Institutes of Health). To establish the threshold of background of fluorescence, sections 
of the images that contained no cells were measured for the mean intensity of fluorescence. The 
white light images provided the guidelines for selecting areas with no cells present. Several 
sections of the background were measured and averaged to perform a background subtraction. 
The fluorescence intensity of each individual cell in every image was measured and the 
background subtraction was performed to determine if the cell was apoptotic. To create an even 
more robust threshold for apoptotic activity, the fluorescence intensities of cells determined to be 
non-fluorescent using the background subtraction method were utilized to create a secondary 
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apoptotic threshold. This calculation, which was based on the limit of detection equation, took 
the mean plus three times the standard deviation to establish a more accurate threshold. Cells 
which surpassed this threshold were considered apoptotic, showing general caspase activation.  
For the baseline activation studies, every image was processed individually, with its own 
unique average background. The temporal trial images were converted to a stack of images in 
ImageJ, and the plugin MeasureStack was utilized to measure every image in the stack to 
monitor the fluorescence of individual cells over the course of the experiment. This allowed for 
the determination of the onset time and duration of caspase activity. White light images taken 
from the binding affinity study were analyzed by counting pre-wash and post-wash cells utilizing 
the multi-select tool in ImageJ. For the green light images from the binding affinity study, 
individual apoptotic thresholds were established for the pre-wash and post-wash images to allow 
for a comparison of the quantities of caspase-exhibiting cells that were observed.  
 
2.9 Safety Considerations 
 Jurkat cells are classified as biosafety level one (BSL-1) organisms. Proper guidelines for 
handling and sanitation and precautions for blood borne pathogens were followed. Sub-culturing 
and harvesting of the cells was conducted in a laminar-flow hood, BSL-2. Gloves, lab coats, and 
eye protection were worn when applicable. Any item that encountered cells was cleaned with 
70% ethanol prior to disposal in a biohazard waste bin. Items that were re-used for multiple 
studies, including syringes utilized for PBS, and the glass micro-capillary utilized in the devices, 
were cleaned thoroughly with ethanol prior to re-use. Ethanol, which is highly flammable, was 
kept away from sources of heat. Proper handling of DMSO was conducted when applicable to 
prevent the absorption of harmful chemicals into the skin. Syringes lacked needles, eliminating 
	 28 
the need for sharps disposal. Care was taken to ensure that the LED fluorescent lights in the 
microscope did not pose an optical threat. The positive control in these studies, doxorubicin, is 
an antineoplastic chemotherapy drug that is mutagenic, carcinogenic, and teratogenic. Since the 
doxorubicin was also housed in DMSO, extra care was taken to prevent exposure and absorption 
through the skin. Nitrile gloves and proper protective clothing and goggles were worn when 
handling doxorubicin. When possible, doxorubicin was handled in a biosafety cabinet to limit the 




3.1 Baseline Caspase Study 
 To determine the general window of caspase activity following the six-hour 
incubation period, a baseline caspase study was conducted for each drug. The results of the 
baseline studies were utilized to select a six-hour window for the device temporal dynamics 
trials. To measure when caspase activity began following treatment, the percentage of apoptotic 
cells in each fluorescence image was determined utilizing the background subtraction and non-
fluorescent cell thresholds. The percentages of apoptotic cells in each image for the three drugs, 
as well as the positive and negative controls, are displayed in Figure 9. Sample images for each 
drug and the controls are shown in Figure 10. Aggregation was observed in each trial of 
dexlansoprazole and esomeprazole, but not seen with omeprazole or the positive control. All 
three drugs showed increased caspase activity over time, which was extrapolated from the 
percentage of apoptotic cells observed at each timestamp. For dexlansoprazole, general caspase 
activity was shown to reach 50% apoptotic cells between hours eighteen and twenty-one; this 
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corresponded to twelve and fifteen hours after the incubation period.  
Dexlansoprazole also showed comparative caspase activity to cells treated with the 
positive control, doxorubicin (100 µM), at hour 30 (Figure 9). Cells treated with omeprazole 
reached 50% apoptosis between hours twenty-one and twenty-four, corresponding to fifteen and 
eighteen hours post-incubation. Esomeprazole showed heightened activity between hours 
twenty-four and twenty-seven, or eighteen and twenty-one hours post-incubation. The positive 
control, cells treated with doxorubicin, showed very high caspase activity within the first six 
hours of the experiment (Figure 9), which persisted through hour thirty. Cells in the negative 
control group showed markedly lower caspase activity until hour thirty of the experiment. These 
initial results were utilized to obtain the window of activation, the six-hour period preceding 
when the percentage of apoptotic cells reached fifty-percent, for each drug. 
 
Figure 9: Percentage of apoptotic cells by hour for each drug. Error bars represent standard 
deviation for three trials. Percent apoptosis corresponds to general caspase activity. Experimental 
drugs show increased caspase activity over time, with dexlansoprazole showing comparable 
activity to the positive control drug, doxorubicin (100 µM), at hours 27 and 30.  
	 30 
 
Figure 10: T=0 fluorescence images (a-e), T=30 fluorescence images (f-j), and T=30 white light 
images (k-o) for each sample. All experimental drugs showed visible fluorescence by hour thirty, 
compared to the negative control. Dexlansoprazole and esomeprazole showed a high degree of 
aggregation that was not observed with the other samples. Scale bar indicates 0.25 mm. 
Fluorescence images enhanced for clarity. 
 
 
3.2 Microfluidic Device Temporal Trials 
 Appropriate six-hour windows where caspase activation might occur were selected for 
each drug. For dexlansoprazole, cells were observed in a microfluidic device from hours fourteen 
to twenty-two. Omeprazole-treated cells were observed from hours eighteen to twenty-four. 
Cells treated with esomeprazole were observed from hours twenty-two to twenty-six. The results 
of these selected windows showed no evidence of caspase activation after repeated trials. It was 
theorized that, due to the microenvironment being much different in the device than in the 
culture dish, caspase induction and subsequent apoptosis were occurring either much earlier or 
much later than the windows viewed in the baseline study.  
To check for caspase activity within the thirty-hour window utilized in the baseline study, 
cells treated with each drug were observed on devices from zero to six, six to twelve, twelve to 
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eighteen, eighteen to twenty-four, and twenty-four to thirty hours. For every six-hour time-
period, all three experimental samples showed no detectable fluorescence (Figure 11). This was 
compared to the positive control, doxorubicin-treated cells, which had a caspase onset time of 
3.66 ± 1.67 hours (from three experiments, with n = 100 cells), and the negative control, which 
showed no significant fluorescence in any time window. Additionally, microfluidic device 
temporal trials displayed a low percentage of experimental cells that successfully bound to the 
affinity surface. It was hypothesized that PPI exposure alters the cellular surface receptors in 
some capacity, reducing the ability of the treated cells to bind to the device’s channel. A binding 
study was necessary to confirm that this phenomenon was specific to PPI-treated cells.  
 
Figure 11: Fluorescence images and accompanying end-stage white light images from the 
microfluidic device temporal trials. Timestamps are provided for each image. Doxorubicin 
shows a high degree of fluorescence by hour six of the experiment, while the experimental drugs 
show very few fluorescent cells throughout thirty hours of experiments. Experimental drug 
images are from different trials, each spanning six hours for a total of thirty hours of observation 
per drug. Images enhanced for clarity. 
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3.3 Binding Affinity Study 
 The results of the binding study confirm the correlation between PPI-exposure and lower 
binding affinity. Binding percentages calculated from the respective pre-wash and post-wash 
images at each time interval are shown in Figure 12, with sample pre-wash and post-wash 
images displayed in Figure 13. Cells treated with any of the three PPI drugs showed a 
measurably lower binding affinity that tended to decrease over time. Notably, experimental drugs 
showed binding affinities comparable to the negative control at hour zero upon initial exposure 
to the PPI drugs. However, by hour six of incubation with the drugs, experimental cells showed 
approximately a 50% decrease in binding affinity. The negative control was run in triplicate, 
with each trial accompanying one of the experimental samples, and the results of the three trials 
were averaged. The control was shown to maintain roughly the same binding affinity throughout 
the thirty-hour experiment, as was consistent with anticipated results. To further eliminate 
possible sources of discrepancy between the binding affinities of the experimental samples and 
the controls, the same microfluidic device was utilized for every experiment. A previous binding 
study had shown the antibody coat to remain viable over the course of a week if the device was 
washed with 1x PBS in between experiments; to ensure the function of the antibody coat, these 
experiments were run consecutively over the course of three days. Additional images were taken 
showing the fluorescence of the cells pre-wash and post-wash (Figure 14). These images were 





Figure 12: Percentage of bound cells for each drug by hour, taken from the percentage of cells 
leftover after the PBS wash. PPI-treated cells all show a dramatically reduced binding affinity 
immediately following the 6-hour drug incubation period. This phenomenon is not observed with 
the negative control, the data for which was averaged from three separate trials. Each individual 
negative control accompanies one of the experimental groups. The same cells were used for both 
the experimental sample and its respective negative control. All samples were tested on the same 
microfluidic device, providing negative control data in triplicate. Error bars represent the 










Figure 13: Sample pre-wash and post-wash images for each drug and the negative control. 
These images were taken twenty-four hours into the experiment for each sample. Cells are 
numbered in green. The negative control shows roughly the same quantity of cells in both the 
pre-wash and post-wash images, whereas the experimental samples show a significant reduction 
in cell number. This translates to a binding affinity that remains unchanged for the negative 





Figure 14: Pre-wash and post-wash fluorescence images for each drug, corresponding to the 
white light images in Figure 13. The negative control was not utilized as a comparison here 
because there was no fluorescence observed. Experimental drugs appear to lose roughly half of 
the fluorescent cells that are present prior to the PBS wash. It is currently unclear whether lack of 
binding is correlated to caspase activity, or whether it is a random effect. Arrows indicate 




 The results of the baseline caspase study revealed the approximate window where 
caspase activity increased for each drug, allowing for the selection of the six-hour period for the 
temporal trials. Given that this study served as a preliminary assessment, it was performed in 
triplicate to verify the results of each trial. The caspase study confirmed that all three of the PPI 
drugs are capable of inducing caspase-dependent apoptosis following six hours of exposure to 
1.0 mM of drug (Figure 9). The 1.0 mM concentration for the PPIs was selected from a prior 
study by Scaringi et al., which showed measurable levels of apoptosis in Jurkat cells following 
exposure to this concentration. Dexlansoprazole showed the most promising caspase activity out 
of the three experimental drugs; it displayed comparable activity to the positive control, 
doxorubicin, at hours twenty-seven and thirty. While the concentration of the dexlansoprazole 
was much higher than that of doxorubicin (1.0 mM versus 100 µM), the achievement of a 
comparable level of activity is noteworthy.  
Doxorubicin is one of the most powerful chemotherapeutic drugs ever administered in a 
clinical setting, and can kill cancer cells at any stage of maturity (Johnson-Arbor and Dubey, 
2021). It has been utilized in clinical practice since the 1960s for the treatment of acute 
lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, and small cell lung 
cancer. Doxorubicin’s primary method of action is intercalation within the DNA, inhibiting DNA 
and RNA synthesis. It also inhibits topoisomerase II, leading to DNA damage that induces 
mitochondrial apoptosis, alongside free radical-mediated cell death and ferroptosis (Johnson-
Arbor and Dubey, 2021). Its mechanism of inducing cellular death via mitochondrial-mediated 
apoptosis and its non-cell-cycle-specific targeting makes it a comparable positive control to the 
PPI drugs. Despite the concentration difference between the positive control and the 
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experimental PPIs, the incidence of dexlansoprazole showing comparative activity to that of 
doxorubicin confirms its potential for further evaluation as a standalone therapeutic.  
Since D2R is utilized to monitor general caspase activity, the window of activation for the 
baseline study encompassed both the initiation and execution stages of apoptosis, rather than 
highlighting the activity window for specific caspases. The D2R probe is suitable for the 
detection of both the intrinsic and extrinsic pathways of apoptosis (Martinez, 2010). Care was 
taken in selecting the appropriate six-hour observation period for temporal trials from the 
baseline study, since initial caspase activity is present even in the negative control group.  
Apoptosis is a normal process that occurs constantly in a healthy population of cells (Elmore, 
2007), meaning that some level of caspase activity should be observed for any given sample of 
cells. All three of the PPI drugs showed less than twenty percent apoptotic cells in the first 
twelve hours of the experiment.  
The higher levels of activity seen in the negative control at hour thirty are likely 
attributable to low cell and medium volume in the culture dish by the end of the experiment. 
Once the cells were re-suspended in complete medium after the incubation period, no additional 
media changes were performed so as not to disturb the cells. The removal of aliquots of cells for 
imaging reduced the total volume leftover in the dish, potentially causing the remaining cells to 
use up available nutrients in the medium and begin to undergo starvation. These cells may also 
be undergoing apoptosis as a result and would be included in the measured levels of caspase 
activity. However, the experimental samples for each drug show elevated caspase activity much 
earlier on in the timeline and with a notably higher intensity than the negative control. 
Furthermore, the levels of apoptosis seen in this study differ from normal levels of apoptosis that 
are observed in a healthy population of Jurkat cells. Jurkat cells are an immortalized line of 
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lymphocytes that were derived from a 14-year-old boy with T cell acute lymphoblastic leukemia 
(Bartelt et al., 2009). Immortalized cell lines can proliferate indefinitely, so a very small number 
of cells will actively undergo apoptosis in a culture of Jurkat cells provided they are given 
sufficient medium and growth conditions (Bartelt et al., 2009). Two-tailed, paired t-tests 
performed with the experimental drug versus the negative control at each time point showed that 
the effect of each drug on apoptosis levels was statistically significant (p < 0.0001 for n = 100 
cells, with a confidence interval of 95%). This finding indicates that most of the apoptotic 
activity seen in the experimental cells is the result of PPI exposure triggering caspase activation.  
These results revealed that caspase-dependent apoptosis in Jurkat cells, resulting from 
PPI treatment, is a late-onset process that does not intensify for at least twelve to fifteen hours 
following the incubation period. This finding contrasts the early onset time seen in the positive 
control, doxorubicin, which showed approximately 90% caspase activity within the first six 
hours of exposure (Figure 9). Doxorubicin has an elimination half-life of at least twenty and up 
to forty-eight hours (Gabizon et al., 2003 and Johnson-Arbor and Dubey, 2021). Omeprazole has 
an elimination half-life of thirty minutes to one hour (Cederberg et al., 1989). Esomeprazole has 
a half-life of one to one and a half hours. Dexlansoprazole has a dual delayed-release formula 
intended to create two peaks of therapeutic activity, and a half-life of one to two hours (Strand et 
al., 2017).  
Dexlansoprazole is designed to become active first at a pH of 5.5, and later at a pH of 
6.75 (Gasiorowska, 2017). The cancer cell microenvironment pH ranges from 5.6 to 6.8 (Lin et 
al., 2019). Omeprazole and esomeprazole become active just once at a pH of approximately 5.4 
(Navarro et al., 1998 and Kim et al., 2019), meaning that the average cancer cell’s 
microenvironment may not be acidic enough to trigger the activation of these drugs. Since 
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dexlansoprazole’s secondary activation is designed to take place at 6.75, it is much more likely 
to be triggered by the average cancer cell. Given that dexlansoprazole showed the greatest 
efficacy of inducing caspase activity out of the experimental drugs, it may be hypothesized that 
its dual-release formula, with the second release occurring at a higher pH, enhances its ability to 
trigger apoptosis in Jurkat cells. This is further evidenced by dexlansoprazole’s comparative 
caspase activity to that of doxorubicin at hour thirty (Figure 9).  
This study conducted an acute drug exposure rather than a chronic, multi-day exposure. 
Clinical administration of doxorubicin is normally performed intravenously in twenty-one day 
intervals (Johnson-Arbor and Dubey, 2013), meaning chemotherapy requires chronic exposure to 
the drug. Doxorubicin still showed effectiveness in this acute exposure due to its capabilities as a 
potent antineoplastic agent. The concentration of each PPI drug was maintained at 1.0 mM for all 
treatments, and direct incubation of the cells with the target drug occurred for six hours. This 
concentration is very high, and likely much higher than what would normally be prescribed in a 
clinical setting. The goals of this study were to assess the apoptotic induction capabilities of the 
PPIs in an acute exposure, and future experiments may be conducted to assess whether the PPIs 
can induce caspase activity in a chronic exposure over multiple days or weeks at a lower 
concentration. Since chemotherapy is normally carried out for several months or indefinitely to 
eliminate and control tumor growth, these PPIs could be tested in a similar schedule as common 
chemotherapeutics to determine their effectiveness. Dexlansoprazole may be particularly 
effective in a chronic exposure due to its dual-release mechanism, meaning it is able to maintain 
therapeutic levels in the body for an extended period compared to the other PPIs. Determining 
the temporal dynamics of caspase activation on an individual-cell basis may enhance the ability 
to outline a successful chronic exposure, highlighting the need for viable microfluidic device 
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temporal trials in future studies. 
 The initial windows of activation selected from the baseline study showed very little 
fluorescence observed for each sample of treated cells. Doxorubicin showed a high degree of 
caspase activity within the first six hours of exposure (Figure 11), confirming that the structure 
of the device allows for the occurrence and visualization of fluorescence. It is theorized that the 
baseline study timeline for activation differs from that of the device due to the difference in 
conditions of the micro-environment to a culture dish. The microfluidic device represents an 
environment that is more physiological in nature, as it allows for gas exchange and provides a 
constant allotment of moving medium. Cells bound to the affinity surface can expunge toxins 
and waste that is carried away by the movement of the medium; cells in the culture dish must 
remain suspended in their own waste. It is also possible that the culture dish cells show greater 
accumulation of D2R over time as the cells are in static medium, and diffusion of the cleaved, 
fluorescent R110 molecule out of the cell may have occurred more slowly. This may have led to 
an amplified fluorescence signal long after the caspase cascade had already begun.  
Troubleshooting the caspase activation window for the experimental drugs required five 
separate temporal assays each, to search the entire window of activity observed in the baseline 
study. These assays monitored cells during the incubation period and up to twenty-four hours 
following the incubation period. To directly observe cells during the six-hour incubation period 
with the target drug, the PPI was added to the FBS-PBS-D2R and PBS syringes at a 
concentration of 1.0 mM. The drug was added to both syringes to ensure the cells were 
constantly exposed to the drug throughout the course of the experiment. Cells were exposed to 
the fluorescent probe consistently for the duration of the experiment, apart from the five-minute 
periods of PBS washing that preceded every imaging round. Despite constant drug and 
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fluorescent probe exposure, none of the selected time windows showed significant caspase 
activity. Several factors may influence the absence of fluorescence seen in the microfluidic 
device temporal trials, with pH being the common denominator. PPIs are inactive in basic 
conditions, but become active as inhibitors in an acidic environment (Walsh, 2015). In the 
baseline activation studies where cells were suspended in medium in a culture dish, the waste 
products excreted by the cancer cells accumulated in solution, resulting in the acidification of the 
extracellular environment.  
The PPI drug added to this dish would become active in this environment, conferring its 
caspase induction ability. However, in the microfluidic device temporal trials, the cells are 
subjected to exposure to a constant influx of PBS at a pH of 7.4, meaning the channel 
environment was slightly alkaline throughout the duration of the experiment. This may have 
counteracted the microenvironment acidification of the cancer cells, resulting in the inactivation 
of the PPI drugs. This would mean the drugs’ apoptotic induction capabilities were not taking 
effect, and would result in an absence of caspase activity. In the future, an assessment of the pH 
of the culture dish over the course of the thirty-hour experiment will be desirable for confirming 
this link. If the culture dish is shown to have a drastically lower pH than the 7.4 PBS, additional 
microfluidic device trials should be conducted with an acidic PBS buffer to determine if caspase 
activity is present. If so, this would mean that PPIs may only trigger the induction of the caspases 
if the extracellular environment is maintained at an acidic pH. 
Cells treated with PPIs showed a lower binding affinity to the microfluidic device’s 
antibody ladder than the negative control (Figure 12). In current applications, PPIs target the 
H+/K+-ATPase system, a specific V-ATPase, found at the secretory surface of gastric parietal 
cells (Masaoka, 2008). It is known that V-ATPases play a role in the regulation of tumor pH, and 
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V-ATPase is overexpressed on the cell surface in multiple cancer cell lines (Chueca et al., 2016). 
Since PPIs target proton pumps located on the cellular surface, it is not unreasonable to expect 
the cell membrane to be affected in other ways by exposure to these drugs. The antibody utilized 
in this study, anti-CD71, is utilized for the capture of cells expressing the transferrin receptor 
(TfR). TfR, a 95 kDa homodimeric type II transmembrane glycoprotein, regulates cell growth 
(Loisel et al., 2011). TfR is overexpressed in multiple cancer cell lines (Kasibhatla et al., 2005), 
meaning this antibody is a useful tool for cell affinity chromatography studies, and shows a high 
binding affinity for multiple types of cancer. Anti-CD71 is not known to induce apoptosis in 
Jurkat cells, making it ideal for studies where cell capture for the purposes of inducing apoptosis 
via another drug is desired (Reif, 2009). 
Although TfR expression is known to be growth-dependent, its expression in Jurkat cells 
can be predicted based on the sub-culturing schedule. TfR is expressed at low levels in non-
proliferating cells, but is intensely upregulated during proliferation (Brell et al., 2020). Since 
Jurkat cells have a doubling cycle of approximately one-to-two days (Schoene and Kamara, 
1999), cells were selected for the microfluidic device trials three-to-four days after sub-culturing 
to maximize expression of TfR. This means that the lowered binding affinity of the experimental 
cells is not attributable to low expression of TfR alone, especially with the negative control of 
the same cell population exhibiting normal levels of binding. An alternate antibody, anti-TCR, 
was utilized in the initial temporal dynamics trials, but was shown to have a poor binding affinity 
for the cells after the six-hour incubation with the target drug, even when cells were harvested at 
various initial growth stages. Anti-TCR binds cells expressing the T-cell receptor protein on the 
cellular surface and has been utilized widely in conjunction with Jurkat cells (Abraham, 2004). 
Unlike TfR, the T-cell receptor protein is not growth-dependent, and should not suffer from the 
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same obstacles in binding that may accompany the anti-CD71 antibody. Since both proteins are 
expressed on the outer membrane of the cellular surface, and both antibodies displayed lower 
binding percentages in the experimental samples, it can be theorized that the TfR and T-cell 
receptor proteins are affected in some way by PPI exposure, reducing their density on the cellular 
surface and resulting in a lower binding percentage for PPI-treated cells. Exposure to the PPIs 
may also alter the physical shape of the membrane, potentially preventing the proteins from 
being exposed to and contacting the antibody ladder on the microfluidic device. 
The aggregation observed in cells treated with dexlansoprazole and esomeprazole (Figure 
12) was consistent throughout the repeated trials, and most often began after hour twelve of the 
experiment. This aggregation may play a role in the reduction in binding affinity seen in the cells 
following PPI exposure. Aggregation was not present in the experimental cells prior to treatment 
with the PPIs, and was not found in the doxorubicin-treated cells or the negative control. This 
suggests that dexlansoprazole and esomeprazole induce this effect directly, although the 
mechanism for this action is unknown. Aggregation does not appear to be correlated to the 
inhibitor drug’s ability to induce apoptosis. While dexlansoprazole showed a high degree of 
aggregation and was also the most potent drug, esomeprazole showed comparative degrees of 
aggregation, but was the least potent of the three drugs. Omeprazole, which showed no evidence 
of aggregation in any of the studies, induced higher levels of apoptosis than esomeprazole.  
An important distinction between the aggregated and non-aggregated cell groups was the 
solvent utilized to dissolve the PPIs. Dexlansoprazole and esomeprazole were both dissolved in 
DMSO, while omeprazole was dissolved in PEG 200. The selection of the PEG 200 solvent for 
omeprazole was made according to the study by Scaringi et al., and was intended to replicate the 
methods outlined in that study. However, dexlansoprazole and esomeprazole are highly insoluble 
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in PEG 200, and were instead dissolved in DMSO. Since doxorubicin was also dissolved in 
DMSO and showed no aggregation, there is no evidence to suggest that the DMSO was 
contaminated. However, this does indicate a possible link between PPI exposure and aggregation 
that may be disrupted by the presence of PEG 200. While PPIs are not known to directly induce 
cell aggregation, they are known to enhance platelet aggregation and clot formation (Wu et al., 
2019) in patients with bleeding peptic ulcers.  
Their ability to enhance aggregation of the platelets may also be present in cancer cells, 
resulting in the treated cells sticking to each other in a manner not seen in untreated cells. This 
phenomenon remains unconfirmed and largely unexplored. However, PEG 200’s role in 
eliminating this aggregation in the omeprazole-treated cells may be speculated. PEG derivatives 
are known to be capable of modulating protein aggregation (Rajan et al., 2006). If the PPIs are 
altering the cancer cells’ surface receptor proteins and leading to aggregation, the PEG 200 
solvent the omeprazole is housed in may modulate this ability, leading to the absence of 
aggregation. In future studies, cells may be treated with omeprazole dissolved in DMSO to 
determine if aggregation occurs. The aggregation may be responsible for the low binding 
affinities observed in the binding study. If the link between aggregation and PPI exposure can be 
solidified, methods may be produced that can circumvent the reduction in binding affinity, 
allowing for the completion of successful microfluidic device temporal dynamics trials. 
The use of the microfluidic devices for individual-cell analysis has many benefits. 
Primarily, the ability to observe the caspase activity onset and duration of a single cell allows for 
a much more precise characterization of the temporal dynamics. However, the initial lack of 
fluorescence and the low binding affinity of the experimental samples presented challenges to 
the viability of these experiments. It was hypothesized that the window of caspase activation 
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could be somewhere within the thirty-hour time-frame, but cells expressing caspase activity were 
selectively unable to bind. Without sufficient binding, and with the possibility that cells 
exhibiting caspase activity were selectively unable to bind, cells could not be observed for 
temporal analysis utilizing the microfluidic devices. These results warranted a binding affinity 
study to assess whether the link between PPI exposure and lower binding percentages was 
significant. If this link could be validated, it could allow for the selection of an antibody whose 
antigen remains unaffected by PPI exposure.  
 The results of the binding study strongly suggested a link between PPI exposure and 
reduced binding affinity of the cells to the affinity surface (Figure 12). All three of the 
experimental drugs showed a significant decrease in the percentage of cells that successfully 
bound to the device following the six-hour incubation period. The experimental cells showed a 
binding affinity roughly the same as that of the negative control at hour zero, prior to the 
incubation period. The negative control cells maintained their binding affinity at roughly eighty-
percent throughout the thirty-hour experiment. To ensure that a comparison was possible, the 
same cells were utilized for the experimental samples and their respective controls. The same 
microfluidic device was utilized for all three of the consecutive experiments, with a re-coating of 
anti-CD71 occurring every twenty-four hours to maintain viability. These results suggest that the 
lowering in observed binding affinities is attributable to PPI treatment. Since this experiment was 
only conducted with a singular trial for the experimental cell groups, additional replicates are 
needed to verify results.  
 With respect to the temporal dynamics assays originally intended to be performed, the 
binding affinity study presents an obstacle. With the drastic reduction in the binding affinity of 
cells post-treatment, it becomes more difficult to capture a suitable quantity of cells for caspase 
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detection. The reduction in binding affinity may be related to the lack of fluorescence observed 
in the microfluidic temporal trials over the course of the thirty-hour period. Fluorescent and non-
fluorescent cells are both shown to be subject to removal during the wash (Figure 14), in what 
appears to be equal likelihoods, meaning that the reduction in binding affinity appears to be 
random and not correlated to the presence of caspase activity in the cell. 
Another possibility is that non-fluorescent-apparent cells that cannot bind may be 
undergoing apoptosis, but are not yet exhibiting enough fluorescent for detection by the time 
points in the binding study. If caspase-expressing cells are selectively unable to bind to the anti-
CD71 antibody ladder following exposure, this renders the use of the microfluidic devices for 
single-cell observation unviable as of now. In the future, the identification of an antibody that 
maintains cellular binding capabilities following PPI exposure would allow for the microfluidic 
temporal trials to continue. Obtaining a suitable antibody would also allow for longer 
microfluidic device experiments, allowing for the characterization of the entire duration of 
caspase activity on an individual-cell basis. Identifying the duration of caspase activity seen in 
both doxorubicin and the experimental drugs could be beneficial for outlining a complete 
timeline for caspase induction and activity, furthering the possibilities of targeted caspase 
therapies involving PPIs. The selection of a different antibody may offer additional benefits as 
well. 
The selection of the anti-CD71 antibody, which targets only the TfR receptor, was made 
to reduce non-specific binding wherever possible, while maintaining a high binding affinity to 
allow for a large quantity of observable cells. This antibody has displayed growth-dependent 
variations in binding affinities in previous studies (Brell et al., 2020). To ensure that a sufficient 
quantity of cells was being captured during the temporal trials, sub-cultures were performed on a 
	 46 
schedule to reduce the number of discarded cells and conserve medium. Cells were utilized three 
days after each sub-culture, when the colony displayed a golden-orange color (Figure 15) and a 
high confluency. The cells were shown to give the best binding affinity when in this stage of 
growth. Failure to follow the strict sub-culturing schedule led to failed experiments due to a low 
quantity of observable cells. Successful microfluidic device experiments were required to have at 
least one hundred bound and observable cells to reduce standard error and ensure validity of 
results. For these trials to produce viable results, the alternate antibody must show a high binding 
affinity that is not hindered by PPI exposure. 
 
Figure 15: Optimal cell color utilized in the microfluidic device trials, including the binding 
affinity study and the initial temporal analysis trials. Sub-cultures were performed weekly, with 
cells incubating for at least three days following sub-culturing before they were used in any 
experiments. This allowed for optimal expression of growth-dependent TfR for binding. 
 
The microfluidic devices presented another experimental challenge. Due to the sensitivity 
of the glass micro-capillary and the likelihood of the channel malfunctioning, the temporal 
experiments had a success rate of approximately fifty percent. The most common source of 
	 47 
device failure was residual PDMS polymer present in the microfluidic channel (Figure 16), 
which led to channel obstructions or the development of bubbles which removed bound cells. 
Bubbles were also produced in the PBS and FBS-PBS syringes. When a bubble entered the 
channel, the field of vision was impeded, and most bound cells were removed (Figure 17). In 
cases where cells remained bound but bubbles could not be dislodged from the field of vision, 
the bubbles impeded analysis and made the contrast of the fluorescence images unbalanced 
(Figure 18). This presented a major problem for this study, as the six-hour timeframe was critical 
to elucidating the temporal dynamics. Once cells were removed from the channel by a bubble, 
the experiment had to be cancelled, resulting in wasted resources. Restarting the six-hour 
temporal observation was not possible, as the cells were on a schedule that began with the PPI 
incubation. Restarting the experiment would disrupt the sensitive timeframe. In future studies 
when possible, the use of machined devices or the addition of a de-bubbler in the tubing setup 
could increase the success rate of the temporal trials. 
 
Figure 16: Residual PDMS at the point where the glass micro-capillary meets the opening of the 
microfluidic channel. The glob of PDMS impedes the flow of liquid from the capillary into the 




Figure 17: A section of the microfluidic device channel that was prone to the development of 
bubbles (top) and a later image of a bubble obstructing the entire field of vision (bottom). This 
phenomenon was common and unfortunately led to the failure of multiple experiments, which 
had to be redone. 
 
 
Figure 18: A bubble in the field of vision of an unenhanced fluorescence image. The presence of 





 Strengthening the microfluidic devices and eliminating bubbles would also allow for 
extended-view trials. These trials would be beneficial for capturing the entire window of caspase 
activity, provided that a suitable antibody could be selected for use in the cells exposed to the 
PPIs. Doxorubicin, which had an average onset time of 3.66 ± 1.67 hours, showed persistent 
caspase activity throughout the remainder of the six-hour experiment following the onset. The 
standard six-hour microfluidic device experiments were too short to reliably depict the entire 
window of caspase activity. A more robust microfluidic device setup would allow for an 
extension of the observation period to a total of nine hours, allowing for the characterization of 
the entire timeline of caspase activity following doxorubicin exposure. This would be a valuable 
comparison tool for the caspase activity durations of other anti-cancer agents, including PPIs, to 
further the possibilities of developing targeted caspase-therapies in the future. 
This study verified that all three experimental PPI drugs induce late-stage apoptosis in 
Jurkat cells via the use of the D2R general caspase probe. This study confirmed that the 
fluorescence observed in the positive control and PPI-treated cells was directly proportional to 
caspase activity, since the D2R probe is suitable for the detection of general caspase activity. 
However, it is also worth noting that caspases have been implicated in the pathways of some 
forms of programmed necrotic cell death (Yuan, 2016). Since apoptosis is desired over necrosis 
due to the lack of inflammatory response and less disruption to the overall system (Kurosaka et 
al., 2003), it would be useful to distinguish between the two. To further confirm that the cell 
death observed in this study is due to caspase activity in apoptosis, and not necrosis or another 
form of cell death, additional methods of verification are desired in future studies. Annexin V is 
a protein that binds to phosphatidylserine on the plasma membrane of apoptotic or necrotic cells, 
and is utilized for staining (Crowley et al., 2016). Propidium iodide is a fluorescent dye that can 
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only penetrate the cell membranes of necrotic cells. Co-staining with Annexin V and propidium 
iodide would allow for the determination of which cells are apoptotic and which cells are 
necrotic (Crowley et al., 2016). This procedure would verify that observed caspase activity is 
solely due to apoptosis, strengthening the results of this study. 
 The results of this study did not attempt to examine the mechanism for how PPIs trigger 
caspase activation, but this information may be desirable in future studies. In a prior study, 
lysosomal damage was implicated as a factor in the onset of apoptosis following the treatment of 
Jurkat cells with omeprazole (Scaringi et al., 2003). The percentage of cells with lysosomal 
perturbations was shown to increase parallel to the percentage of apoptotic cells, indicating that 
lysosomal damage led to the triggering of caspase-dependent apoptosis (Scaringi et al., 2003). 
Since the PPIs in this study function similarly, future experiments may examine whether the 
caspase activity seen in dexlansoprazole and esomeprazole is related to damage to the Jurkat 
cells’ lysosomes. This examination may be performed utilizing acridine orange staining. 
Acridine orange is a fluorescent dye that readily accumulates in the lysosomes; if the lysosomal 
membrane is compromised, the dye will leak out into the cytosol, where it can be detected 
(Scaringi et al., 2003). Determining if lysosomal damage is a key factor in triggering the caspase 
cascade following PPI treatment would provide additional insights on how these drugs may act 
as anti-cancer agents. 
 
5. CONCLUSION 
The purpose of this study was to verify the presence of and characterize the temporal 
dynamics of caspase activity in Jurkat cells following exposure to the proton pump inhibitors 
dexlansoprazole, omeprazole, and esomeprazole. Fluorescence microscopy allowed for the 
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observation of caspase activity in treated cells over a period of thirty hours on a multi-cell and 
individual-cell basis. The fluorogenic probe in this study, D2R, is rapidly up-taken by the cancer 
cells and readily cleaved by caspases within the apoptotic cascade. Cleavage of D2R releases the 
fluorophore R110 which diffuses out of the cell very slowly. Caspase activity is thus directly 
correlated to fluorescence intensity observed in the cells during real-time observation. A baseline 
caspase activation study verified that all three of the experimental drugs induce significant 
caspase activity in the cells following six hours of incubation with 1.0 mM of PPI drug, with 
dexlansoprazole showing the highest efficacy of induction (Figure 9). Microfluidic devices were 
utilized to capture cells to an affinity surface for real-time determination of caspase activation. 
While the microfluidic devices were not initially suitable for the temporal dynamics studies due 
to low observed fluorescence and low quantities of bound cells, these challenges led to the 
development of a binding affinity study. This study showed that PPI exposure reduces the 
binding affinity of the cells to the affinity surface following the incubation period (Figure 12), 
indicating that PPIs alter the cell surface receptors in some fashion. 
 Future studies will verify that the cell death observed in this work is largely attributable 
to apoptosis via Annexin V staining. Additionally, the identification of a suitable antibody for 
use in the microfluidic device temporal trials will allow for a further exploration of caspase 
activity on an individual-cell basis. Extended-view microfluidic device trials will allow for the 
characterization of the entire duration of caspase activity resulting from doxorubicin exposure 
and PPI exposure, aiding in creating a timeline for the entire caspase cascade that follows drug 
treatment. This study may also be modified to lower the concentrations of the PPI drugs and 
instead focus on a chronic exposure, to monitor the occurrence of caspase activity in Jurkat cells 
following less-potent, but more frequent contact with the PPIs. Finally, other PPI drugs may be 
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assessed for their apoptosis-inducing capabilities, particularly those which might employ a dual-
release formula. These future studies will expand upon the results of this work, aiding in 
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